46 related articles for article (PubMed ID: 15228371)
1. Injectable biologic case studies.
Lipsy RJ
J Manag Care Pharm; 2004 May; 10(3 Suppl):S10-6; quiz S20. PubMed ID: 15228371
[TBL] [Abstract][Full Text] [Related]
2. Considerations for assessing the cost of biologic agents in the treatment of psoriasis.
Rich SJ
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S38-41. PubMed ID: 15253689
[TBL] [Abstract][Full Text] [Related]
3. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
Balkrishnan R; Bhosle MJ; Fleischer AB; Feldman SR
J Dermatolog Treat; 2010 May; 21(3):178-84. PubMed ID: 19821787
[TBL] [Abstract][Full Text] [Related]
4. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
Bukstein DA
Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
[TBL] [Abstract][Full Text] [Related]
5. Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations.
Lipsy RJ; Fuller MG; Roski J; Mansukani S
J Manag Care Pharm; 2004 May; 10(3 Suppl):S4-9; quiz S19. PubMed ID: 15228370
[TBL] [Abstract][Full Text] [Related]
6. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
7. Cross-sectional analysis of the relationship between national guideline recommended asthma drug therapy and emergency/hospital use within a managed care population.
Nestor A; Calhoun AC; Dickson M; Kalik CA
Ann Allergy Asthma Immunol; 1998 Oct; 81(4):327-30. PubMed ID: 9809496
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prasugrel in a US managed care population.
Mauskopf JA; Graham JB; Bae JP; Ramaswamy K; Zagar AJ; Magnuson EA; Cohen DJ; Meadows ES
J Med Econ; 2012; 15(1):166-74. PubMed ID: 22066985
[TBL] [Abstract][Full Text] [Related]
9. Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
[TBL] [Abstract][Full Text] [Related]
10. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
Sullivan PW; Nair KV; Patel BV
Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
[TBL] [Abstract][Full Text] [Related]
11. The use of therapeutic interchange for biologic therapies.
Flood J; Mihalik C; Fleming RR; Strober BE; Zucker DR; Burgoyne DS
Manag Care; 2007 Jan; 16(1):51-62. PubMed ID: 17285813
[TBL] [Abstract][Full Text] [Related]
12. Value of biologic therapy: a forecasting model in three disease areas.
Paramore LC; Hunter CA; Luce BR; Nordyke RJ; Halbert RJ
Curr Med Res Opin; 2010 Jan; 26(1):41-51. PubMed ID: 19895366
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature.
Fleurence R; Spackman E
J Rheumatol; 2006 Nov; 33(11):2124-31. PubMed ID: 17086602
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy: strategies to control drug costs in managed care.
Monane M; Nagle B; Kelly MA
Geriatrics; 1998 Sep; 53(9):51-4, 63; quiz 64. PubMed ID: 9745626
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
[TBL] [Abstract][Full Text] [Related]
16. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
Cohen M; Morrow T; Penna P
Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Casciano J; Amaya K; Doyle J; Arikian S; Shear N; Haspel M; Kahler K
Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
[TBL] [Abstract][Full Text] [Related]
18. Back to the future: the managed care approach to rheumatoid arthritis.
Sidorov J
Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of asthma practices.
Stempel DA
Am J Manag Care; 2000 Oct; 6(17 Suppl):S930-6; discussion S937-9. PubMed ID: 11184564
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Tang DH; Armstrong EP; Lee JK
Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
